Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Amy J. Davidoff, PhD, Jessica B Long, MPH, Natalia Neparidze, MD, Jan Philipp Bewersdorf, MD, Rory M. Shallis, MD, Nikolai A. Podoltsev, MD PhD, Rong Wang, PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD MPH

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140728

Published: 2020

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133855

Published: 2020

Journal Articles

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134718

Published: 2020

Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137734

Published: 2020

Journal Articles

Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study

Suleyman Y Goksu, MD, Jude Khatib, MD, Busra N Bacik Goksu, Rong Wang, PhD, Prapti A. Patel, MD, Madhuri Vusirkala, MD, Suzanne Cole, MD, Ahmet Seyhanli, MD, Muhammet Ozer, MD, Robert H. Collins, MD, Stephen Chung, MD, Amer M. Zeidan, MBBS, MHS, Yazan F. Madanat, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140564

Published: 2020

Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139752

Published: 2020

Journal Articles

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Rory M. Shallis, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-139428

Published: 2020

Journal Articles

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Amer M. Zeidan, MBBS, MHS, Adrienne M. Gilligan, PhD, Santosh Gautam, PhD, David L. Grinblatt, MD, Dina Elsouda, Loretta Sullivan, MD MPH, Bhavik J. Pandya, PharmD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136366

Published: 2020

Journal Articles

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Hongbo Yang, PhD, Andy Garnham, MSc, Manasee V. Shah, MPH, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-136184

Published: 2020

Journal Articles

Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Rong Wang, PhD, Rory M. Shallis, MD, Jan Philipp Bewersdorf, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD MPH, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139468

Published: 2020

Journal Articles

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Prajwal C Boddu, MBBS, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-139668

Published: 2020

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Blood (2020) 136 (Supplement 1): 49–51.

https://doi.org/10.1182/blood-2020-136922

Published: 2020

Journal Articles

Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Rory M. Shallis, MD, Rong Wang, PhD, Jan Philipp Bewersdorf, MD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD MPH, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139531

Published: 2020

Journal Articles

The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents

Namita Joshi, PhD MS, BPharm, Hrishikesh P Kale, PhDMS,BPharm, Shelby Corman, PharmD, MS, BCPS, Kala Hill, Tim Wert, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-139642

Published: 2020

Journal Articles

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia

Jan Philipp Bewersdorf, MD, Stephanie Prozora, BS, MD, Rong Wang, PhD, Nikolai A. Podoltsev, MD PhD, Rory M. Shallis, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Xiaomei Ma, PhD, Steven D. Gore, MD, Amer M. Zeidan, MBBS, MHS, Amy J. Davidoff, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-136983

Published: 2020

Journal Articles

Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis

Jan Philipp Bewersdorf, MD, Martin S. Tallman, MD, Christina Cho, MD, Amer M. Zeidan, MBBS, MHS, Maximilian Stahl, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-136671

Published: 2020

Journal Articles

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-137232

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Amer M. Zeidan, MBBS, MHS, Rong Wang, PhD, Xiaoyi Wang, MD MPH, Rory M Shallis, MD, Nikolai A. Podoltsev, MD PhD, Jan Philipp Bewersdorf, MD, Scott F. Huntington, MD MPH, Natalia Neparidze, MD, Smith Giri, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 646.

https://doi.org/10.1182/blood-2019-127398

Published: 2019

NARROW

Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia

Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only